Innovation for dialysis has a major impact on the lives of patients with end stage kidney failure. The Biohybrid Kidney XB Program group is seeking partnerships with companies interested in co-developing membrane technology, (synthetic) cell technology, material sciences and micro electromechanical systems for (semi-) implantable artificial kidneys and similar devices.

In this program healthcare organisations, knowledge institutions and technology companies from South Holland are brought together around the central question how labor-saving and -relieving technology can be optimized and deployed to ensure the quality and accessibility of care with fewer personnel.

This PPP program focuses on the major societal challenges surrounding cardiovascular health. The aim of the cardiovascular agenda is for cardiovascular health to be measurably better in 2030 than it is today, with the reduction of health inequalities in society as an important spearhead.

FORESIGHT is transforming drug development by using advanced molecular imaging to track medicines in the body and identify the best treatment for each patient. This innovative approach makes drug development faster, more effective, and more personalized, helping to bring better treatments to those who need them most.

The IMPACT program aims to advance machine perfusion technologies for organ preservation, assessment, and repair. By collaborating with top institutions and private partners, it drives innovative solutions to improve organ viability, enhance regeneration, and reduce immunogenicity, strengthening the Netherlands' position as a global leader in transplantation.

The number of people with dementia in the Netherlands who live longer and without (in)formal care is growing rapidly. In addition, the staff shortage in healthcare is growing. The DEMTECH program focuses on technologies that promote self-management, making these people less dependent on external care.

Since 2020, ORANGEHealth has been active as a partnership of all seven Dutch knowledge institutions - universities and universities of applied sciences - in the field of oral healthcare. ORANGEHealth benefits from the unique oral care system, with periodic checkups, and establishes an integrated role of the oral healthcare professional in the broader healthcare system.

Stroke is a large, societal problem: one out of four in the Netherlands will get a stroke, with huge consequences for the patient and for society. PP CONTRAST will develop innovative approaches for improving both diagnosis and treatment of patients with a stroke.

In this program, UMC Utrecht works together with Amsterdam UMC, two health funds/patient organizations and 34 professional associations, patient organizations and companies (Long Alliance Netherlands) in developing and making applicable innovative treatments for patients with hereditary lung diseases, like cystic fibrosis and primary ciliary dyskinesia.

One in two Dutch people will develop cancer, of which 20% is a rare cancer (including childhood cancers). REACT-NL, a collaboration between KWF, KiKa, and Oncode Institute, aims at improving the diagnostics and treatment of rare tumours. The program stimulates innovation within public-private partnerships, with emphasis on valorization, to enhance patient outcomes.